<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925233</url>
  </required_header>
  <id_info>
    <org_study_id>KY20182079-F-1</org_study_id>
    <nct_id>NCT03925233</nct_id>
  </id_info>
  <brief_title>Breast Cancer Treatment Based on Organ-like Culture</brief_title>
  <official_title>Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Organ-like Culture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the breast cancer organ platform, this experiment establishes a drug sensitivity
      test method that is closer to the body tumor in breast cancer, provides a basis for the
      accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer
      drug resistance.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of cell viability</measure>
    <time_frame>8 weeks before neoadjuvant chemotherapy</time_frame>
    <description>1. The organ-like organ was assayed for cell viability using CellTiter Glo 3D reagent, and the curve was used to obtain a half-inhibitory concentration range. The dose was adjusted according to the half-inhibition concentration range to obtain an accurate half-inhibitory concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of in vitro model drug sensitivity</measure>
    <time_frame>8 weeks before neoadjuvant chemotherapy</time_frame>
    <description>2. In vitro model drug sensitivity: sensitive and insensitive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy assessment according to RECIST criteria</measure>
    <time_frame>8 weeks before neoadjuvant chemotherapy</time_frame>
    <description>Clinical efficacy evaluation according to RECIST criteria: imaging ultrasonography, histological pathology.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer Organoids</condition>
  <arm_group>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab Injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Doxorubicin Hydrochloride Injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin hydrochloride</intervention_name>
    <description>Epirubicin hydrochloride injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Fluorouracil injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Endostatin</intervention_name>
    <description>Recombinant Human Endostatin Injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirarubicin hydrochloride</intervention_name>
    <description>Pirarubicin hydrochloride injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrrolidine</intervention_name>
    <description>Pyrrolidine tablets</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixabepilone</intervention_name>
    <description>Ixapilone Injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen citrate</intervention_name>
    <description>Tamoxifen citrate tablets</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine tartrate</intervention_name>
    <description>Vinorelbine tartrate injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin mesylate</intervention_name>
    <description>Eribulin mesylate injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toremifene citrate</intervention_name>
    <description>Toremifene citrate tablets</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Anastrozole tablets</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole tablets</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Exemestane tablets</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Olapani pill</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib mesylate</intervention_name>
    <description>Apatinib mesylate tablets</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pattozumab</intervention_name>
    <description>Pattozumab injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine tablets</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ear particles</intervention_name>
    <description>Ear particles</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aidi Injection</intervention_name>
    <description>Aidi Injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide injection</description>
    <arm_group_label>ER+ Breast Cancer</arm_group_label>
    <arm_group_label>HER2+ Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        With the prolongation of human life and lifestyle changes, the incidence and mortality of
        cancer has increased year by year. Since 2010, cancer has become the leading cause of
        death. Among women, the incidence of breast cancer is the highest, and it shows a growing
        trend, which seriously threatens women's health. Breast cancer has a high degree of tumor
        heterogeneity, which leads to a great difference in sensitivity to chemotherapy among
        affected individuals. The drug resistance after chemotherapy leads to poor prognosis.
        Therefore, screening for breast cancer tumor cells is sensitive to chemotherapy. Molecular
        level studies of drug resistance are necessary.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with breast cancer and the largest tumor diameter ≥ 3cm No previous chemotherapy
        regimen age 18-65 years old Can obtain the tumor tissue specimens required for culture
        Heart, liver, kidney and bone marrow hematopoietic function is good Know and sign the
        informed consent form

        Exclusion Criteria:

        Pregnant or lactating women Also suffering from other cancer patients There are serious
        uncontrolled medical diseases or acute infections Those who are known to be allergic to
        this study drug or a variety of previous drugs The patient cannot understand the purpose of
        the study or disagree with the requirements of the study.

        Other investigators believe that patients who are not suitable for this study group
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>JingSu</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug sensitivity experiment</keyword>
  <keyword>Resistance mechanism research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Toremifene</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Endostatins</mesh_term>
    <mesh_term>Pirarubicin</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

